Efficacy and Toxicity of Folfoxiri for Patients with Metastatic Colorectal Cancer

Huy, Trịnh Lê; Bui, My; Dinh, Toi Chu; Xuyen, Hoang Thi Hong

doi:10.3889/oamjms.2019.368

Cited by 2 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The FOLFOXIRI regimen showed promising outcomes with a PFS of 13.37 ± 9 months, an overall response rate of 79.4%, a significant decrease in the risk of early disease progression, and side effects within the acceptable range for mCRC first-line therapy ( Huy et al, 2019 ). More importantly, the FOLFOXIRI regimen increased the rate of radical surgery for initially unresectable mCRC, and the long-term survival of radically resected patients was particularly notable, with a benefit of 42% and 33% in 5- and 8-year survival rates, respectively ( Masi et al, 2009 ).…”

Section: Combination Therapies Based On Irinotecanmentioning

confidence: 99%

The effective combination therapies with irinotecan for colorectal cancer

Chai,

Liu,

Zhang

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Colorectal cancer is the third most common type of cancer worldwide and has become one of the major human disease burdens. In clinical practice, the treatment of colorectal cancer has been closely related to the use of irinotecan. Irinotecan combines with many other anticancer drugs and has a broader range of drug combinations. Combination therapy is one of the most important means of improving anti-tumor efficacy and overcoming drug resistance. Reasonable combination therapy can lead to better patient treatment options, and inappropriate combination therapy will increase patient risk. For the colorectal therapeutic field, the significance of combination therapy is to improve the efficacy, reduce the adverse effects, and improve the ease of treatment. Therefore, we explored the clinical advantages of its combination therapy based on mechanism or metabolism and reviewed the rationale basis and its limitations in conducting exploratory clinical trials on irinotecan combination therapy, including the results of clinical trials on the combination potentiation of cytotoxic drugs, targeted agents, and herbal medicine. We hope that these can evoke more efforts to conduct irinotecan in the laboratory for further studies and evaluations, as well as the possibility of more in-depth development in future clinical trials.

show abstract

Section: Combination Therapies Based On Irinotecanmentioning

confidence: 99%

The effective combination therapies with irinotecan for colorectal cancer

Chai,

Liu,

Zhang

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Given the limited therapeutic options in metastatic BTC and the promising results of FOLFIRINOX/folinic acid, fluorouracil, oxaliplatin, and irinotecan (FOLFOXIRI) in other malignancies, it is compelling to investigate this combination in the context of BTC [ 12 , 13 ]. This manuscript presents the results of a phase 2 trial evaluating the efficacy and safety of FOLFIRINOX in patients with metastatic BTC.…”

Section: Introductionmentioning

confidence: 99%

Phase II Trial of FOLFIRINOX in Advanced Biliary Tract Cancer

Bazarbashi,

Aseafan,

Elshenawy

et al. 2024

Cureus

View full text Add to dashboard Cite

Introduction: Biliary tract cancers (BTCs), characterized by poor prognosis and limited treatment options, are increasingly prevalent malignancies with a five-year survival rate of less than 20% for advanced-stage disease. The standard first-line chemotherapy combining gemcitabine and cisplatin offers modest survival benefits, necessitating the exploration of more effective therapies. This study reports the results of a single-arm, open-label, phase 2 trial assessing the efficacy and safety of fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFIRINOX) as a first-line treatment for metastatic or locally advanced unresectable BTC. Methods: Patients aged ≥18 with measurable disease and adequate organ function were enrolled, receiving biweekly FOLFIRINOX for up to 12 cycles with follow-up imaging every four cycles. The primary endpoint was the overall response rate (ORR), with progression-free survival (PFS), overall survival (OS), and safety as secondary endpoints. Results: Thirteen patients were enrolled from December 2016 to September 2021 before early termination due to slow accrual and the emergence of immunotherapy. The ORR was 54%, with a disease control rate of 77%. Median PFS and OS were 6.8 and 19.25 months, respectively. Grade 3/4 toxicities were predominantly hematologic, with neutropenia being the most common severe adverse event. Conclusion: The trial suggests that FOLFIRINOX is a potentially effective first-line therapy for unresectable or metastatic BTC with a manageable safety profile. However, the early termination of the study and the introduction of immunotherapy warrant further research to confirm these findings.

show abstract

Efficacy and Toxicity of Folfoxiri for Patients with Metastatic Colorectal Cancer

Cited by 2 publications

References 14 publications

The effective combination therapies with irinotecan for colorectal cancer

The effective combination therapies with irinotecan for colorectal cancer

Phase II Trial of FOLFIRINOX in Advanced Biliary Tract Cancer

Contact Info

Product

Resources

About